Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Alltracel Pharmaceuticals Plc announces Nanopeutics Agreement

Abstract:
Alltracel's Nanopeutics subsidiary signs new Professional Wound Care technology development agreement with ConvaTec

Alltracel Pharmaceuticals Plc announces Nanopeutics Agreement

DUBLIN, Ireland | Posted on November 11th, 2007

Alltracel Pharmaceuticals Plc., ("Alltracel" or "the Company"), (AIM:AP.L), the
healthcare innovation group focused on oral care, wound care, cardiovascular
health and dermal health markets, today announces that its Nanopeutics
subsidiary has signed a collaborative technology development agreement with
ConvaTec, a world-leading manufacturer of ostomy and wound care products with a
25-year heritage of caring for patients.


ConvaTec has been working with Alltracel since November 2006, when the initial
primary concept development agreement was announced with a professional wound
care partner. As per the original agreement, today's new technology agreement
will be funded by ConvaTec and its successful conclusion may lead to an
exclusive royalty bearing license and supply agreement between both companies.


As part of the development work under the previous agreement, Alltracel's
healthcare services division (Alltracel Healthcare Services) was also contracted
by ConvaTec to perform laboratory testing and analysis work. The extension of
the collaboration between Alltracel and ConvaTec will also include similar
laboratory testing and analysis work by Alltracel Healthcare Services.


Alltracel's Chief Executive Officer, Tony Richardson commented:


"We are very pleased to announce our continuing collaboration with ConvaTec. Our
new agreement in the area of professional wound care product development further
supports the strength of Alltracel's development work carried out to date for
ConvaTec and we look forward to progressing the commercialisation of our
professional wound care products in 2008 and beyond. The professional wound
care area is an important market for us and we are happy to be collaborating
with a partner of ConvaTec's caliber and heritage. Alltracel's Nanospider(TM)
technology affords many possibilities in this sector and seeks to improve
product performance and assist in the treatment of many patients."


Michael J Lydon PhD, Vice President Global R&D in ConvaTec commented:


"ConvaTec acknowledges the significant commercial opportunities that
nanotechnology presents in the field of professional wound care. This agreement
recognizes our continuing commitment to develop this technology to enhance
products and offer improved wound care solutions for our patients."

####

About Alltracel
Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.

Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.

With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.

Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:

Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovative technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, Dermal Health and Cardiovascular Health.

- Alltracel's specialist Oral Care subsidiary Synpart Limited
(www.synpartlimited.com) with offices in the UK and Germany is the leading
contract supply and manufacturing partner for the European private label
inter-dental market and also partners with a number of leading oral care brands
internationally.

- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of Nanospider(TM)technology for the global
healthcare market.

- Alltracel Healthcare Services provides Scientific Research, Clinical
Trial & Development Services for Healthcare companies seeking a step up in speed
of Healthcare Innovation.

Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas such as Wound Care, Oral Care, Cardiovascular
Health and Dermal Health.

ConvaTec Information

ConvaTec, a world-leading manufacturer of ostomy and wound care products with a
heritage of caring about patients, is a Bristol-Myers Squibb Company (NYSE: BMY).
Bristol-Myers Squibb is a global pharmaceutical and related health care
products company.

ConvaTec's Wound Therapeutics(TM)franchise pursues a comprehensive approach that
grounds our advanced science in the everyday realities of wound and skin care.
The company's Chronic Care franchise develops innovative products and
product-related services to help people with an ostomy get back to their
everyday activities and live their lives to the fullest. For more information
please visit www.convatec.com.

Wound Therapeutics(TM)is a trademark of ConvaTec, a Division of E.R. Squibb &
Sons, LLC

m-doc(TM)& Phytopeutics(TM)are trademarks of Alltracel Pharmaceuticals plc.

Nanospider(TM)and Nanopeutics(TM)are trademarks controlled by Nanopeutics s.r.o.

For more information, please click here

Contacts:
Dublin: Karen Muldowney
Alltracel: +353 1 235 2162


London: Deborah Scott
Financial Dynamics: +44 207 831 3113

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Announcements

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Patents/IP/Tech Transfer/Licensing

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B October 6th, 2016

Research partnerships

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Novel silicon etching technique crafts 3-D gradient refractive index micro-optics November 28th, 2016

Single photon converter -- a key component of quantum internet November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project